Trial Profile
A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Dose of NKTR-358 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Rezpegaldesleukin (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly and Company
- 10 Nov 2019 Status changed from active, no longer recruiting to completed, according to a Nektar Therapeutics media release.
- 10 Nov 2019 According to a Nektar Therapeutics media release, data from this study were presented at the 2019 Annual Meeting of the American College of Rheumatology in Atlanta.
- 10 Nov 2019 Results presented in a Nektar Therapeutics media release.